The combination of EPA+DHA and low-dose aspirin ingestion reduces platelet function acutely whereas each alone may not in healthy humans

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 87, Issue 4-5, 2012, Pages 143-151

  Block, Robert C ^a   Kakinami, Lisa ^a,b   Jonovich, Matthew ^a   Antonetti, Illena ^a   Lawrence, Peter ^c   Meednu, Nida ^a   CalderonArtero, Pedro ^a   Mousa, Shaker A ^d   Thomas Brenna, J ^c   Georas, Steve ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c Department of Obstetrics Gynecology   (United States)

^d ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Acetylsalicylic acid; Aspirin; Docosahexaenoic acid; Eicosapentaenoic acid; Omega 3 fatty acids; Platelet function; Platelet function analyzer 100

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOGENIC FACTOR; AUTOTAXIN; CYTOKINE; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDYLCHOLINE; OMEGA 3 ACID ETHYL ESTER; PLACEBO;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD SAMPLING; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; HUMAN EXPERIMENT; LOW DRUG DOSE; MALE; NORMAL HUMAN; OUTCOME ASSESSMENT; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; THROMBOCYTE FUNCTION; TREATMENT DURATION;

ASPIRIN; BLOOD PLATELETS; DOCOSAHEXAENOIC ACIDS; DRUG COMBINATIONS; EICOSAPENTAENOIC ACID; HUMANS; PLATELET FUNCTION TESTS;

EID: 84867234433     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2012.08.007     Document Type: Article

References (71)

1. Jemal A., Ward E., Hao Y., Thun M. Trends in the leading causes of death in the United States, 1970-2002. J. Am. Med. Assoc. 2005, 294(10):1255-1259.
2. Krasopoulos G., Brister S.J., Beattie W.S., Buchanan M.R. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. Br. Med. J. 2008, 336(7637):195-198.
3. Bucher H.C., Hengstler P., Schindler C., Meier G. n-3 Polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am. J. Med. 2002, 112(4):298-304.
4. Lemaitre R.N., King I.B., Mozaffarian D., Kuller L.H., Tracy R.P., Siscovick D.S. n-3 Polyunsaturated fatty acids, fatal ischemic heart disease, and nonfatal myocardial infarction in older adults: the cardiovascular health study. Am. J. Clin. Nutr. 2003, 77(2):319-325.
5. Iso H., Rexrode K.M., Stampfer M.J., Manson J.E., Colditz G.A., Speizer F.E., et al. Intake of fish and omega-3 fatty acids and risk of stroke in women. J. Am. Med. Assoc. 2001, 285(3):304-312.
6. -Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999, 354:447-455. GISSI.
7. Kris-Etherton P.M., Harris W.S., Appel L.J. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002, 106:2747-2757.
8. Block R.C., Harris W.S., Reid K.J., Sands S.A., Spertus.J.A. EPA and DHA in blood cell membranes from acute coronary syndrome patients and controls. Atherosclerosis 2008, 197(2):821-828.
9. Gurbel P.A., Bliden K.P., DiChiara J., Newcomer J., Weng W., Neerchal N.K., et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007, 115(25):3156-3164.
10. Ohmori T., Yatomi Y., Nonaka T., Kobayashi Y., Madoiwa S., Mimuro J., et al. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J. Thromb. Haemost. 2006, 4(6):1271-1278.
11. Dyerberg J., Bang H.O., Stoffersen E., Moncada S., Vane J.R. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis?. Lancet 1978, 2(8081):117-119.
12. Terano T., Hirai A., Hamazaki T., Kobayashi S., Fujita T., Tamura Y., et al. Effect of oral administration of highly purified eicosapentaenoic acid on platelet function, blood viscosity and red cell deformability in healthy human subjects. Atherosclerosis 1983, 46(3):321-331.
13. Patrono C., Garcia Rodriguez L.A., Landolfi R., Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N. Engl. J. Med. 2005, 353(22):2373-2383.
14. Campbell C.L., Smyth S., Montalescot G., Steinhubl S.R. Aspirin dose for the prevention of cardiovascular disease: a systematic review. J. Am. Med. Assoc. 2007, 297(18):2018-2024.
15. Hansson L., Zanchetti A., Carruthers S.G., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. HOT Study Group, Lancet 1998, 351(9118):1755-1762.
16. Fredman G., Van Dyke T.E., Serhan C.N. Resolvin E1 regulates adenosine diphosphate activation of human platelets. Arterioscler. Thromb. Vasc. Biol. 2010, 30(10):2005-2013.
17. Dona M., Fredman G., Schwab J.M., Chiang N., Arita M., Goodarzi A., et al. Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets. Blood 2008, 112(3):848-855.
18. Serhan C.N., Chiang N., Van Dyke T.E. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 2008, 8(5):349-361.
19. Gajos G., Rostoff P., Undas A., Piwowarska W. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 Fatty Acids after PCI to Modify Responsiveness to Dual Antiplatelet Therapy) study. J. Am. Coll. Cardiol. 2010, 55(16):1671-1678.
20. Lev E.I., Solodky A., Harel N., Mager A., Brosh D., Assali A., et al. Treatment of aspirin-resistant patients with omega-3 fatty acids versus aspirin dose escalation. J. Am. Coll. Cardiol. 2010, 55(2):114-121.
21. Aoki J. Mechanisms of lysophosphatidic acid production. Semin. Cell Dev. Biol. 2004, 15(5):477-489.
22. Wu W.T., Chen C.N., Lin C.I., Chen J.H., Lee H. Lysophospholipids enhance matrix metalloproteinase-2 expression in human endothelial cells. Endocrinology 2005, 146(8):3387-3400.
23. Lucas A., Grynberg A., Lacour B., Goirand F. Dietary n-3 polyunsaturated fatty acids and endothelium dysfunction induced by lysophosphatidylcholine in Syrian hamster aorta. Metabolism 2008, 57(2):233-240.
24. Panchatcharam M., Miriyala S., Yang F., Rojas M., End C., Vallant C., et al. Lysophosphatidic acid receptors 1 and 2 play roles in regulation of vascular injury responses but not blood pressure. Circ. Res. 2008, 103(6):662-670.
25. Schmitz G., Ruebsaamen K. Metabolism and atherogenic disease association of lysophosphatidylcholine. Atherosclerosis 2010, 208(1):10-18.
26. Yoshida K., Nishida W., Hayashi K., Ohkawa Y., Ogawa A., Aoki J., et al. Vascular remodeling induced by naturally occurring unsaturated lysophosphatidic acid in vivo. Circulation 2003, 108(14):1746-1752.
27. Umezu-Goto M., Kishi Y., Taira A., Hama K., Dohmae D., Takio K., et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J. Cell Biol. 2002, 158(2):227-233.
28. van Meeteren L.A., Ruurs P., Stortelers C., Bouwman P., van Rooijen M.A., Pradere J.P., et al. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol. Cell. Biol. 2006, 13:5015-5022.
29. Celletti F.L., Waugh J.M., Amabile P.G., Brendolan A., Hilfiker P.R., Dake M.D. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat. Med. 2001, 4:425-429.
30. Lamon B.D., Hajjar D.P. Inflammation at the molecular interface of atherogenesis: an anthropological journey. Am. J. Pathol. 2008, 173(5):1253-1264.
31. Marchioli R., Barzi F., Bomba E. On behalf of the GISSI-Prevenzione Investigators. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002, 105:1897-1903.
32. Garaiova I., Guschina I.A., Plummer S.F., Tang J., Wang D., Plummer N.T. A randomised cross-over trial in healthy adults indicating improved absorption of omega-3 fatty acids by pre-emulsification. Nutr. J. 2007, 6:4.
33. Sanderson S., Emery J., Baglin T., Kinmonth A.L. Narrative review: aspirin resistance and its clinical implications. Ann. Intern. Med. 2005, 142(5):370-380.
34. Kundu S.K., Heilmann E.J., Sio R., Garcia C., Davidson R.M., Ostgaard R.A. Description of an in vitro Platelet Function Analyzer-PFA-100. Semin. Thromb. Hemost. 1995, 21(Suppl. 2):106-112.
35. Mammen E.F., Comp P.C., Gosselin R., Greenberg C., Hoots W.K., Kessler C.M., et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin. Thromb. Hemost. 1998, 24(2):195-202.
36. Gum P.A., Kottke-Marchant K., Poggio E.D., Gurm H., Welsh P.A., Brooks L., et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am. J. Cardiol. 2001, 88(3):230-235.
37. Borna C., Lazarowski E., van Heusden C., Ohlin H., Erlinge D. Resistance to aspirin is increased by ST-elevation myocardial infarction and correlates with adenosine diphosphate levels. Thromb. J. 2005, 3:10.
38. Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler. Thromb. Vasc. Biol. 2004, 24(11):1980-1987.
39. Block R.C., Duff R., Lawrence P., Kakinami L., Brenna J.T., Shearer G.C., et al. The effects of EPA, DHA, and aspirin ingestion on plasma lysophospholipids and autotaxin. Prostaglandins Leukot. Essent. Fatty Acids 2010, 82(2-3):87-95.
40. Ferguson C.G., Bigman C.S., Richardson R.D., van Meeteren L.A., Moolenaar W.H., Prestwich G.D. Fluorogenic phospholipid substrate to detect lysophospholipase D/autotaxin activity. Org. Lett. 2006, 8(10):2023-2026.
41. Andersen K., Hurlen M., Arnesen H., Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb. Res. 2002, 108(1):37-42.
42. Hobikoglu G.F., Norgaz T., Aksu H., Ozer O., Erturk M., Nurkalem Z., et al. High frequency of aspirin resistance in patients with acute coronary syndrome. Tohoku J. Exp. Med. 2005, 207(1):59-64.
43. McCabe D.J., Harrison P., Mackie I.J., Sidhu P.S., Lawrie A.S., Purdy G., et al. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. Platelets 2005, 16(5):269-280.
44. Abaci A., Caliskan M., Bayram F., Yilmaz Y., Cetin M., Unal A., et al. A new definition of aspirin non-responsiveness by Platelet Function Analyzer-100 and its predictors. Platelets 2006, 17(1):7-13.
45. Pamukcu B., Oflaz H., Onur I., Oncul A., Umman B., Koylan N., et al. Aspirin-resistant platelet aggregation in a cohort of patients with coronary heart disease. Blood Coagul. Fibrinolysis 2007, 18(5):461-465.
46. Ogawa H., Nakayama M., Morimoto T., Uemura S., Kanauchi M., Doi N., et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. J. Am. Med. Assoc. 2008, 300(18):2134-2141.
47. Anfossi G., Russo I., Trovati M. Resistance to aspirin and thienopyridines in diabetes mellitus and metabolic syndrome. Curr. Vasc. Pharmacol. 2008, 6(4):313-328.
48. Sacco M., Pellegrini F., Roncaglioni M.C., Avanzini F., Tognoni G., Nicolucci A., et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003, 26(12):3264-3272.
49. Hovens M.M., Snoep J.D., Eikenboom J.C., van der Bom J.G., Mertens B.J., Huisman M.V. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am. Heart J. 2007, 153(2):175-181.
50. Yusuf S., Reddy S., Ounpuu S., Anand S. Global burden of cardiovascular diseases: Part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001, 104(22):2746-2753.
51. Yusuf S., Hawken S., Ounpuu S., Dans T., Avezum A., Lanas F., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364(9438):937-952.
52. Larson M.K., Ashmore J.H., Harris K.A., Vogelaar J.L., Pottala J.V., Sprehe M., et al. Effects of omega-3 acid ethyl esters and aspirin, alone and in combination, on platelet function in healthy subjects. Thromb. Haemost. 2008, 100(4):634-641.
53. Patrignani P., Filabozzi P., Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J. Clin. Invest. 1982, 69(6):1366-1372.
54. Patrono C., Ciabattoni G., Patrignani P., Pugliese F., Filabozzi P., Catella F., et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 1985, 72(6):1177-1184.
55. FitzGerald G.A., Oates J.A., Hawiger J., Maas R.L., Roberts L.J., Lawson J.A., et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J. Clin. Invest. 1983, 71(3):676-688.
56. McAdam B.F., Catella-Lawson F., Mardini I.A., Kapoor S., Lawson J.A., FitzGerald G.A. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc. Natl. Acad. Sci. USA 1999, 96(1):272-277.
57. Cullen L., Kelly L., Connor S.O., Fitzgerald D.J. Selective cyclooxygenase-2 inhibition by nimesulide in man. J. Pharmacol. Exp. Ther. 1998, 287(2):578-582.
58. Belton O., Byrne D., Kearney D., Leahy A., Fitzgerald.D.J. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000, 102(8):840-845.
59. Pierucci A., Simonetti B.M., Pecci G., Mavrikakis G., Feriozzi S., Cinotti G.A., et al. Improvement of renal function with selective thromboxane antagonism in lupus nephritis. N. Engl. J. Med. 1989, 320(7):421-425.
60. Mene P., Pugliese F., Patrono.C. The effects of nonsteroidal anti-inflammatory drugs on human hypertensive vascular disease. Semin. Nephrol. 1995, 15(3):244-252.
61. Usman M.H., Notaro L.A., Nagarakanti R., Brahin E., Dessain S., Gracely E., et al. Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble?. Am. J. Cardiol. 2009, 103(8):1107-1112.
62. Bays H.E. Safety considerations with omega-3 fatty acid therapy. Am. J. Cardiol. 2007, 99(6A):35C-43C.
63. Lagarde M., Calzada C., Guichardant M., Vericel.E. Dose-effect and metabolism of docosahexaenoic acid: pathophysiological relevance in blood platelets. Prostaglandins Leukot. Essent. Fatty Acids 2012, April 18.
64. Guillot N., Caillet E., Laville M., Calzada C., Lagarde M., Vericel E. Increasing intakes of the long-chain omega-3 docosahexaenoic acid: effects on platelet functions and redox status in healthy men. FASEB J. 2009, 23(9):2909-2916.
65. Serhan C.N. Novel eicosanoid and docosanoid mediators: Resolvins, docosatrienes, and neuroprotectins. Curr. Opin. Clin. Nutr. Metab. Care 2005, 8(2):115-121.
66. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J. 2002, 324(7329):71-86. Antithrombotic Trialists' Collaboration.
67. Harris W.S. Expert opinion: omega-3 fatty acids and bleeding-cause for concern?. Am. J. Cardiol. 2007, 99(6A):44C-46C.
68. Li Z.G., Yu Z.C., Wang D.Z., Ju W.P., Zhan X., Wu Q.Z., et al. Influence of acetylsalicylate on plasma lysophosphatidic acid level in patients with ischemic cerebral vascular diseases. Neurol. Res. 2008, 30(4):366-369.
69. Tomsig J.L., Snyder A.H., Berdyshev E.V., Skobeleva A., Mataya C., Natarajan V., et al. Lipid phosphate phosphohydrolase type 1 (LPP1) degrades extracellular lysophosphatidic acid in vivo. Biochem. J. 2009, 419(3):611-618.
70. de Meijer A., Vollaard H., de Metz M., Verbruggen B., Thomas C., Novakova.I. Meloxicam, 15mg/d, spares platelet function in healthy volunteers. Clin. Pharmacol. Ther. 1999, 66(4):425-430.
71. Jilma B., Fuchs I. Detecting aspirin resistance with the Platelet Function Analyzer (PFA-100). Am. J. Cardiol. 2001, 88(11):1348-1349.